BAT Releases 2024 Fiscal Year Trading Update on December 11th

Dec.11.2024
BAT Releases 2024 Fiscal Year Trading Update on December 11th
BAT announces strong growth in new product categories and traditional tobacco revenues for the second half of 2024 fiscal year.

On December 11, British American Tobacco (BAT) released a trading update for the fiscal year ending 2024. The company stated that the accelerated growth in the second half of 2024 was in line with expectations, primarily driven by innovation in new product categories. Revenue from new product categories and traditional tobacco is expected to increase in the second half of the year compared to the first half.


BAT expects that by the end of 2024, the cash conversion rate will exceed 90%, while the leverage ratio will be within the target range of 2.0-2.5 times. Additionally, they have expressed support for the Canadian Companies' Creditors Arrangement Act (CCAA) and are hopeful to reach a conclusion that is beneficial for all stakeholders.


In the traditional tobacco industry, the United States' business actions continued to gain momentum in the second half of the year; in the AME and APMEA regions, its market share continued to grow. Investments in the first half of the year in the US business actions and wholesale inventory adjustments drove an increase in organic sales volume and financial performance in the traditional tobacco business in the second half of the year. Despite a slight decrease in value share due to the impact of the US market's geographic mix, volume share increased by 20 basis points in key markets.


The performance of new business categories is also improving. Vuse e-cigarettes maintain a leading market share globally, with a 40.3% share in key markets (50.7% share in tracked channels in the U.S.). Meanwhile, the innovative product line of the glo brand is showing signs of accelerated growth in the second half of the year, with new products like glo Hyper Pro driving sales growth. The Velo brand continues to experience strong growth in markets outside the U.S., solidifying its position as a leader in the oral market.


BAT expects a decrease in sales of approximately 2% in 2024, with organic revenue and profit growth forecasted to be in the low single digits. Planned capital expenditure is around 600 million pounds, and net financial expenses are expected to be 1.6 billion pounds, impacted by fluctuations in exchange rates and interest rates.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Ispire Q2 FY2026 revenue falls to $20.3M as it trims lower-quality customers; A/R down nearly 20%
Ispire Q2 FY2026 revenue falls to $20.3M as it trims lower-quality customers; A/R down nearly 20%
Ispire reported a sharp year-on-year revenue decline in Q2 FY2026 as it shifted away from lower-quality customers, while cutting operating expenses and narrowing its net loss. The company also highlighted improved collections, with net accounts receivable down nearly one-fifth since June 30, 2025, alongside ongoing manufacturing and technology initiatives.
Feb.09 by 2FIRSTS.ai
Scientific talk in Bursa Nilüfer spotlights cigarette and e-cigarette addiction and youth risks
Scientific talk in Bursa Nilüfer spotlights cigarette and e-cigarette addiction and youth risks
Nilüfer Municipality in Bursa held a scientific talk titled “Does Addiction Change Form? Cigarettes, E-Cigarettes and Lung Health” as part of February 9 Quit Smoking Day, aiming to raise awareness of the social impact of tobacco addiction. Experts discussed cigarette and e-cigarette addiction, risks for young people, harms of secondhand smoke for children, and health outcomes linked to tobacco use.
Feb.10 by 2FIRSTS.ai
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA officials said manufacturing consistency is a core prerequisite for ENDS PMTA reviews, not a procedural formality. During its February 10, 2026 roundtable, the agency outlined expectations for quality management systems, manufacturing documentation, nicotine control, stability studies, and risk mitigation, emphasizing that robust manufacturing evidence underpins determinations of whether products are appropriate for the protection of public health.
Feb.11
Special Report | Breeze and Glas Seek White House Review as FDA Advances Flavored ENDS Guidance
Special Report | Breeze and Glas Seek White House Review as FDA Advances Flavored ENDS Guidance
Breeze Smoke and Glas, Inc. have separately requested White House review under Executive Order 12866 as the FDA advances draft guidance on flavored ENDS (RIN 0910-ZC78). The guidance aims to clarify evidentiary standards under the statutory “appropriate for the protection of public health” (APPH) framework. The parallel filings highlight industry concern over regulatory predictability, particularly as Glas’s PMTA review status has recently drawn market attention.
Special Report
Mar.03
China Caps E-Cigarette Capacity and Requires Export Compliance Proof to Curb “Involution”
China Caps E-Cigarette Capacity and Requires Export Compliance Proof to Curb “Involution”
China’s top tobacco regulator has issued a directive aimed at preventing excess capacity and curbing “involution-style” competition in the e-cigarette sector. The notice tightens investment controls, formalizes verified capacity management and requires exporters to submit compliance proof for destination markets, signaling a push toward higher industry concentration and stricter cross-border oversight.
Special Report
Feb.13
Belgium Calls for EU-Wide Limits on Vape Ingredients and Ban on Disposable E-Cigarettes
Belgium Calls for EU-Wide Limits on Vape Ingredients and Ban on Disposable E-Cigarettes
Belgian Health Minister Frank Vandenbroucke has called on the European Union to take stronger action on vaping, saying it is becoming an “epidemic” and accusing the industry of targeting young people.
Mar.26 by 2FIRSTS.ai